- Home
- CRNX
CRNX
Crinetics Pharmaceuticals Inc.
as 04-18-2025 1:34pm EST
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $73.36 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.10 - $62.53 | Next Earning Date: | 05-08-2025 |
| Revenue: | $1,039,000 | Revenue Growth: | -74.11% |
| Revenue Growth (this year): | 356.4% | Revenue Growth (next year): | 700.38% |
Stock Insider Trading Activity of Crinetics Pharmaceuticals Inc. (CRNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Struthers Richard Scott | CRNX | President & CEO | Mar 19 '25 | Sell | $34.50 | 17,338 | $593,016.96 | 330,022 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Mar 19 '25 | Sell | $34.50 | 2,515 | $86,021.37 | 72,233 | |
| Betz Stephen F. | CRNX | Chief Scientific Officer | Mar 19 '25 | Sell | $34.50 | 5,770 | $197,352.96 | 108,588 | |
| Knight Jeff E. | CRNX | Chief Operating Officer | Mar 19 '25 | Sell | $34.50 | 7,162 | $244,963.80 | 87,852 | |
| Pizzuti Dana | CRNX | Chief Med and Dev Officer | Feb 3 '25 | Sell | $39.07 | 5,000 | $195,350.00 | 72,233 |
Latest Crinetics Pharmaceuticals Inc. News
CRNX Breaking Stock News: Dive into CRNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
9 days ago
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
23 days ago
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
GlobeNewswire
23 days ago
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
MT Newswires
25 days ago
Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target
GlobeNewswire
a month ago
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
MT Newswires
2 months ago
Crinetics Pharmaceuticals Q4 Net Loss Narrows
Compare CRNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRNX Crinetics Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.